These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 20547314

  • 1. The present and the future landscape of treatment of advanced hepatocellular carcinoma.
    Rimassa L, Santoro A.
    Dig Liver Dis; 2010 Jul; 42 Suppl 3():S273-80. PubMed ID: 20547314
    [Abstract] [Full Text] [Related]

  • 2. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB.
    J Clin Oncol; 2006 Sep 10; 24(26):4293-300. PubMed ID: 16908937
    [Abstract] [Full Text] [Related]

  • 3. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.
    Zhu AX.
    Expert Opin Investig Drugs; 2010 May 10; 19(5):663-72. PubMed ID: 20367287
    [Abstract] [Full Text] [Related]

  • 4. Novel inhibitors in development for hepatocellular carcinoma.
    Wörns MA, Galle PR.
    Expert Opin Investig Drugs; 2010 May 10; 19(5):615-29. PubMed ID: 20374038
    [Abstract] [Full Text] [Related]

  • 5. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
    Chaparro M, González Moreno L, Trapero-Marugán M, Medina J, Moreno-Otero R.
    Aliment Pharmacol Ther; 2008 Dec 01; 28(11-12):1269-77. PubMed ID: 18808443
    [Abstract] [Full Text] [Related]

  • 6. Molecularly targeted therapy in hepatocellular carcinoma.
    Huynh H.
    Biochem Pharmacol; 2010 Sep 01; 80(5):550-60. PubMed ID: 20371362
    [Abstract] [Full Text] [Related]

  • 7. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
    Kudo M, Ueshima K.
    Oncology; 2010 Jul 01; 78 Suppl 1():154-66. PubMed ID: 20616599
    [Abstract] [Full Text] [Related]

  • 8. Sorafenib for the treatment of unresectable hepatocellular carcinoma.
    Kane RC, Farrell AT, Madabushi R, Booth B, Chattopadhyay S, Sridhara R, Justice R, Pazdur R.
    Oncologist; 2009 Jan 01; 14(1):95-100. PubMed ID: 19144678
    [Abstract] [Full Text] [Related]

  • 9. Positioning and indication of sorafenib in the treatment algorithm and real practice setting: Western and eastern approach--Asian perspective.
    Lee JM, Han KH.
    Oncology; 2010 Jul 01; 78 Suppl 1():167-71. PubMed ID: 20616600
    [Abstract] [Full Text] [Related]

  • 10. Sorafenib in advanced hepatocellular carcinoma.
    Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group.
    N Engl J Med; 2008 Jul 24; 359(4):378-90. PubMed ID: 18650514
    [Abstract] [Full Text] [Related]

  • 11. Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now?
    Finn RS.
    Clin Cancer Res; 2010 Jan 15; 16(2):390-7. PubMed ID: 20068087
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, Teufel A, Schuchmann M, Kanzler S, Düber C, Otto G, Galle PR.
    J Clin Gastroenterol; 2009 Jan 15; 43(5):489-95. PubMed ID: 19247201
    [Abstract] [Full Text] [Related]

  • 13. Novel molecular therapies in hepatocellular carcinoma.
    Faivre S, Bouattour M, Raymond E.
    Liver Int; 2011 Jan 15; 31 Suppl 1():151-60. PubMed ID: 21205154
    [Abstract] [Full Text] [Related]

  • 14. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.
    Zhang T, Ding X, Wei D, Cheng P, Su X, Liu H, Wang D, Gao H.
    Anticancer Drugs; 2010 Mar 15; 21(3):326-32. PubMed ID: 20016366
    [Abstract] [Full Text] [Related]

  • 15. Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone.
    Kim HY, Park JW.
    Dig Dis; 2011 Mar 15; 29(3):303-9. PubMed ID: 21829021
    [Abstract] [Full Text] [Related]

  • 16. [Hepatocellular carcinoma].
    Kondo S, Ueno H, Morizane C, Okusaka T.
    Gan To Kagaku Ryoho; 2010 Jul 15; 37(7):1219-23. PubMed ID: 20647702
    [Abstract] [Full Text] [Related]

  • 17. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
    Yau T, Pang R, Chan P, Poon RT.
    Expert Opin Pharmacother; 2010 Sep 15; 11(13):2187-98. PubMed ID: 20707757
    [Abstract] [Full Text] [Related]

  • 18. Targeted therapies for hepatocellular carcinoma.
    Skelton MR, O'Neil B.
    Clin Adv Hematol Oncol; 2008 Mar 15; 6(3):209-18. PubMed ID: 18391920
    [Abstract] [Full Text] [Related]

  • 19. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.
    Peck-Radosavljevic M, Greten TF, Lammer J, Rosmorduc O, Sangro B, Santoro A, Bolondi L.
    Eur J Gastroenterol Hepatol; 2010 Apr 15; 22(4):391-8. PubMed ID: 19940784
    [Abstract] [Full Text] [Related]

  • 20. Targeted therapy of hepatocellular cancer.
    Wysocki PJ.
    Expert Opin Investig Drugs; 2010 Feb 15; 19(2):265-74. PubMed ID: 20074016
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.